APGE241220P80000
- 0.00
- 0.000.00%
Apogee Therapeutics Newsroom
Apogee Therapeutics Is Maintained at Outperform by Wedbush
Guggenheim Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $110
CCORF Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $89
Apogee Therapeutics Initiated at Buy by Canaccord Genuity
Apogee Therapeutics Analyst Ratings
Canaccord Genuity Initiates Coverage On Apogee Therapeutics With Buy Rating, Announces Price Target of $89
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $100
TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $100
TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating
Apogee Therapeutics Price Target Maintained With a $87.00/Share by Wedbush
Apogee Therapeutics Analyst Ratings
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $81
Buy Rating on Apogee Therapeutics' APG808: Market Potential and Treatment Advantages Amid FDA Approval Landscape
BofA Securities Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $80
Apogee Therapeutics, Inc. (APGE) Receives a Buy From TD Cowen
Buy Rating for Apogee Therapeutics: Promising Prospects for Dupixent and APG808 in COPD Market
Buy Rating on Apogee Therapeutics: Promising Drug Developments and Strong Financials
Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics Analyst Ratings